5 results
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC (2.5/5 µg, 5/5 µg), administered once daily by the RESPIMAT Inhaler, after 6 weeks of treatment.
The aim of this study is to assess and compare the pharmacokinetic parameters of the newly developed amlodipine besilate oral liquid 0,5 mg/ml with commercial Norvasc 5 mg tablets. The secondary objective is to assess the taste of the oral liquid.
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 / 5 µg ; 5 / 5 µg) with tiotropium (5 µg), olodaterol (5 µg) and placebo on lung-hyperinflation and endurance time…
The primary objective of the study is to evaluate the effect of tiotropium + olodaterol FDCcompared to tiotropium monotherapy on the intensity of breathlessness during the 3min CSST.A secondary objective is to explore the relationship between…
The aim of this study is to examine the effectiveness of treatment with tDCS in reducing AVH and related symptoms in patients with BPD and AVH